From the Korean healthcare payer’s perspective using the Markov model of a one-month Markov cycle and five-year time horizon, the strategy of EGFR mutation testing before first-line erlotinib administration for advanced lung adenocarcinoma was the dominant option in the base case analysis, compared with the no-testing strategy. This evidence concerns the gene EGFR and lung adenocarcinoma.